What is Immunophotonics?
Immunophotonics is pioneering the emerging field of Interventional Immuno-Oncology, developing IP-001, a novel therapeutic asset designed to convert routine tumor ablation procedures into systemic cancer immunotherapies. The company's technology aims to activate a tumor-specific anticancer immune response, targeting multiple solid tumor indications. Currently in Phase 2 development, Immunophotonics operates globally with bases in St. Louis, Missouri, USA, and subsidiaries in Bern, Switzerland, and Tianjin, China, positioning itself at the forefront of advanced cancer treatment research.
How much funding has Immunophotonics raised?
Immunophotonics has raised a total of $26.3M across 5 funding rounds:
Private Equity
$550K
Private Equity
$2.5M
Series A
$1.8M
Debt
$111K
Series B
$21.4M
Private Equity (2010): $550K, investors not publicly disclosed
Private Equity (2014): $2.5M led by BioGenerator and Cultivation Capital
Series A (2014): $1.8M supported by St Louis Arch Angels, Missouri Technology, BioGenerator, Cultivation Capital, and Billiken Angels Network
Debt (2021): $111K featuring PPP
Series B (2022): $21.4M backed by Zubizoom and AC Immune
Key Investors in Immunophotonics
BioGenerator
BioGenerator is a St. Louis-based entity focused on creating and growing innovative companies, investing through BioGenerator Ventures and providing comprehensive startup support via BioGenerator Labs. They are a key backer in the region's life sciences ecosystem.
Cultivation Capital
Cultivation Capital is a venture capital firm specializing in early-stage to Series B investments across life sciences, software, and agriculture, with a strong focus on the Midwest. They provide capital and strategic network support to help startups achieve hyper growth.
AC Immune
AC Immune is a Swiss biotechnology pharmaceutical company established in 2003, dedicated to the research and development of treatments for neurodegenerative diseases. Their involvement suggests a strategic interest in Immunophotonics' immuno-oncology platform.
What's next for Immunophotonics?
With its recent major strategic investment and substantial overall capital, Immunophotonics is poised for significant advancement. The company is expected to accelerate its Phase 2 clinical trials for IP-001, potentially moving towards later-stage development and regulatory submissions. This financing will likely fuel further research and development, expand its global operational footprint, and strengthen its position in the competitive biotech landscape, particularly within the immuno-oncology sector. The strategic nature of the latest funding suggests potential collaborations or partnerships that could expedite market entry.
See full Immunophotonics company page
